Suchergebnisse - "Laramée, Philippe"

PubPharm (49)

1

The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain

enthalten in: PharmacoEconomics - open | 2024

von Macabeo, B. | Rotrou, T. | Millier, A. | +2

2

The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain

enthalten in: PharmacoEconomics - open | 2023

von Macabeo, B. | Rotrou, T. | Millier, A. | +2

3

Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021

enthalten in: Medical decision making : an international journal of the Society for Medical Decision Making | 2023

von Trouiller, J. | Laramée, P.

4

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma

enthalten in: The European journal of health economics : HEPAC : health economics in prevention and care | 2023

von Trouiller, J. | Nikolaidis, G. | Macabeo, B. | +4

5

Access to innovative drugs and the National Reimbursement Drug List in China : Changing dynamics and future trends in pricing and reimbursement

enthalten in: Journal of market access & health policy | 2023

von Macabeo, B. | Wilson, L. | Xuan, J. | +5

6

Erratum to "Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma : Results from a systematic literature review and a network meta-analysis" [Cancer Treat. Rev. 110 (2022) 102463

enthalten in: Cancer treatment reviews | 2023

von Corrie, P. | Meyer, N. | Berardi, R. | +6

ErratumFor: Cancer Treat Rev. 2022 Nov;110:102463. - PMID 36099854

7

Response to 'considerations regarding a network meta-analysis of targeted therapies for BRAF mutant unresectable or metastatic melanoma'

enthalten in: Cancer treatment reviews | 2022

von Corrie, P. | Meyer, N. | Berardi, R. | +6

CommentOn: Cancer Treat Rev. 2022 Dec;111:102469. - PMID 36244080

8

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France : a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial

enthalten in: BMJ open | 2022

von Trouiller, J. | Macabeo, B. | Poll, A. | +8

9

Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma : Results from a systematic literature review and a network meta-analysis

enthalten in: Cancer treatment reviews | 2022

von Corrie, P. | Meyer, N. | Berardi, R. | +6

CommentIn: Cancer Treat Rev. 2022 Dec;111:102469. - PMID 36244080

10

Potential risks in using midodrine for persistent hypotension after cardiac surgery : a comparative cohort study

enthalten in: Annals of intensive care | 2020

von Tremblay, J. | Laramée, P. | Lamarche, Y. | +6

1
2
3
4
5
Nächster »
[5]